A Phase III study of the drug solanezumab
The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s study (A4 for short), is a clinical research study for older individuals who may be at risk for Alzheimer’s disease (AD).
The A4 study is investigating a drug intervention, solanezumab, that may reduce the impact of a protein known as “amyloid” or “beta amyloid” in the brain. Scientists think that elevated amyloid may play a key role in the development of AD-related mental deterioration. The investigational drug used in A4 targets the excess amyloid in the brain with the aim of slowing the memory and related deterioration associated with the development of AD.
Half the participants in the A4 study will receive the investigational drug, and half will receive a “placebo” (non-active agent used for comparison). The drug and the placebo are given by an intravenous infusion.
Who may be eligible to participate?
*A4 is no longer enrolling.*
For more information, contact Study Coordinator Jessica Nuñez at 215-662-4379 or firstname.lastname@example.org.